Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07449195

A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors

The purpose of this study is to compare two devices used for optical coherence tomography (OCT). OCT is a noninvasive imaging (scanning) method that uses reflected light to create pictures of the back of the eye, and doctors can use OCT to detect and monitor different types of cancer

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ocular Tumor Eye Diseases Eye Neoplasms Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Memorial Sloan Kettering at Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years.
  • At least 1 eye that has an intraocular or ocular surface tumor.
  • The presence of a natural crystalline lens or intraocular lens.
  • Pupils that can dilate up to at least 3 mm in the study eyes.
  • The absence of opaque natural crystalline lenses or the presence of any ocular disease that prevents the view of the retina for imaging.
  • Patients must be able to fixate on the imaging target.
  • Patients must be able to sit still for a period of time (approximately 2 minutes).

Exclusion criteria

  • Does not meet ALL of the above conditions

Treatment and study plan

Intalight Dream OCT

Diagnostic Test

This is a next-generation swept-source device that has a faster imaging speed and higher sensitivity than the previous generation of frequency-domain OCT devices, which serve as the current standard of care devices.

Heidelberg Spectralis OCT

Diagnostic Test

This is the standard of care for optical imaging.

Primary outcomes

  1. Image quality for participants

    Time frame: Up to 1 year

    Evaluated by next-generation swept-source OCT versus standard OCT for imaging of the eye and any relevant ocular tumors.

  2. Field of view for participants

    Time frame: Up to 1 year

    Evaluated by next-generation swept-source OCT versus standard OCT for imaging of the eye and any relevant ocular tumors.

Study contacts

Contact information is provided by the study sponsor or research team.

David Abramson, MD

CONTACT

[email protected]

212-639-7232

Jasmine Francis, MD

CONTACT

[email protected]

212-639-7266

Sponsors and collaborators

Lead sponsor

Memorial Sloan Kettering Cancer Center

Other

Collaborators

  • Intalight, Inc

Registry information

Official study title

Ocular Imaging for Monitoring of Ocular Tumor Disease

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Mar 4, 2026
Registry last updated
May 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.